MRC-Holland - About us - Careers - EN

improved products
P189-CDKL5 Rett syndrome, atypical
P072-MSH6 Hereditary nonpolyposis colon cancer (HNPCC)
P061-Lissencephaly Lissencephaly
P069-Human Telomere-4 Broad subtelomeric screening
P015-MECP2 RETT syndrome
P064-MR-1 Mental Retardation; 1p-deletion, Williams, Smith-Magenis, Miller-Dieker, DiGeorge, Prader-Willi, Alagille, Saethre-Chotzen, Sotos
P237-DNAI1 Primary ciliary dyskinesia (PCD)
P313-CREBBP Rubinstein–Taybi syndrome (RSTS)
P218-LPL LPL deficiency
P205-SH2D1A-XIAP-ITK Lymphoproliferative syndrome
P169-Hirschsprung-1 Hirschsprung disease, or Aganglionic Megacolon
P226-SDH Paragangliomas (PGL)

Are you looking for a job?

Klik hier voor de Nederlandse versie

MRC-Holland is a fast-growing biotechnology company based in the Amsterdam Baarsjes. MRC-Holland consists of a multinational team of about 35 employees. MRC-Holland is the inventor of the Multiplex Ligation-dependent Probe Amplification (MLPA) technique, a sensitive method to detect copy number changes in genes. MLPA is used in numerous applications, from identifying hereditary diseases to investigating genetic alterations in tumors. Our MLPA products are used in hundreds of labs and hospitals worldwide

At this moment we don't have any vacancies.

Newsletter

Home

Site map

Terms and Conditions